Orphazyme admits this may be the end, as it asks court to oversee restructuring

Max Gelman

Senior Editor

Just a couple weeks after Orphazyme admitted European regulators were unlikely to approve its FDA-rejected drug, the biotech indicated it may shut down entirely. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Orphazyme admits this may be the end, as it asks court to oversee restructuring

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Or­p­hazyme ad­mits this may be the end, as it asks court to over­see re­struc­tur­ing

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Orphazyme admits this may be the end, as it asks court to oversee restructuring

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial